Where Pharmacy Sits in the Study
Part of Trial Pharmacy (PHARM) Training: Foundations for the Trial Pharmacy.
About 2 minutes. Free, in your language, no account needed.
Why this matters
Pharmacy interacts with more parties than almost any other site function. Sponsor, depot, courier, investigator, coordinator, nurse, monitor and sometimes an interactive response system.
Knowing who decides what prevents most of the delays and nearly all of the arguments.
Who decides what
The sponsor owns the product and the protocol. Stability judgments, quarantine release after an excursion, and destruction authorization usually sit with them.
The investigator prescribes and is responsible for the participant.
Pharmacy verifies, prepares, dispenses and accounts.
The monitor verifies records and does not make pharmacy decisions.
When a monitor says a temperature excursion is fine, ask who decided. A monitor's opinion is not a sponsor release.
Interactive response systems
Many trials allocate kits and manage supply through a system that assigns a kit number when a participant is randomized or returns for a visit.
The system is the record of allocation. If it says kit 0138, the participant gets 0138.
If the system is unavailable, there is a documented backup procedure. Use it. Do not improvise an allocation and reconcile later.
Supply and forecasting
Running out of product stops a participant's treatment. That is a clinical harm and a protocol deviation at once.
Watch expiry dates against the visit schedule, not against today. A kit that expires in six weeks is not usable for a participant due in eight.
Raise shortages early. Resupply takes longer than anyone expects.
In practice
A participant is due on Friday and the only kit in the right stratum expires Thursday.
You do not wait to see whether the visit slips. You flag it now, to the coordinator and the sponsor, while there is still time to ship.
What this looks like when it goes wrong
A site notices a supply gap three days before a visit. The resupply takes nine days.
The participant misses a dose. The protocol treats that as a major deviation, and depending on the study it may make them unevaluable for the primary endpoint.
The gap was visible in the expiry data six weeks earlier.
Key takeaways
- Know who decides: sponsor for product, investigator for the participant, pharmacy for custody.
- A monitor's reassurance is not a sponsor release.
- The allocation system is the record; use the backup procedure, not improvisation.
- Check expiry against the visit schedule, not against today.